Loading…
Loading…
Get a deeper insight into the potential performance of Ryder (R) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W.
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder's position in the commercial vehicle market and provides buyers with added protec.
Ryder (R) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five dividend growers recently raised payouts as resilient markets face inflation, trade and Fed risks, offering income-focused investors stocks to watch.
In this article series, I summarize dividend announcements of the past week. Eight dividend growth stocks announced increases, with PNC delivering the largest raise of 17.6%. MRSH stands out for high quality and a safe 37% payout ratio, while the stock trades 11% below fair value. FAST extended its 28-year dividend growth streak with an 8.3% increase but trades at a 13% premium to fair value.
Consistent efforts to reward its shareholders through dividend hikes highlight the financial strength of R.
BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the original Pooph products that generated more than $125 million in pet-care sales while under license from BioLargo. WESTMINSTER, CA / ACCESS Newswire / July 13, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that it is preparing to relaunch CupriDyne®-based consumer pet products under a yet-to-be-announced brand.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for R and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.